Lilly Announces Thyroid Cancer Testing Program
FDA Approves Pralsetinib for Metastatic RET Fusion-Positive NSCLC
CMS Issues FY2021 IPPS and LTCH Final Rule
FDA Approves Azacitidine for AML Continued Treatment
FDA Approves Daratumumab + Carfilzomib and Dexamethasone for R/R MM
CMS Extends AUC Program Educational + Operational Testing Period to 2021
NCCN Adds Tafasitamab-cxix to Guidelines for B-Cell Lymphomas
CMS Opens CHART Model Webinar Registration
CMS Opens PFS Listening Session Registration
FDA Approves Belantamab Mafodotin-blmf for R/R Multiple Myeloma
CMS Releases CY 2021 OPPS Proposed Rule
CMS Releases CY 2021 PFS Proposed Rule
FDA Approves Tafasitamab-cxix + Lenalidomide for R/R DLBCL
ASCO Statement on Home Infusions Raises Safety Concerns
FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib in BRAF+ Advanced Melanoma
HHS Report Reveals Dramatic Uptick in Telehealth During Pandemic
Upcoming CMS COVID-19 Stakeholder Calls
CMS Releases Updated Data on COVID-19's Impact on Medicare Population
FDA Approves CAR-T Cell Therapy Brexucabtagene Autoleucel for R/R MCL
HHS Secretary Azar Extends Public Health Emergency
HHS Partners with ECHO Institute for Virtual Telemedicine Learning Community
USPSTF Draft Recommendation Expands Those Eligible for LDCT Lung Cancer Screening
FDA Approves Decitabine + Cedazuridine Oral Combo for Adult MDS
FDA Approves Avelumab for Maintenance Treatment in Advanced Urothelial Carcinoma
FDA Approves Pembrolizumab for First-line Treatment of Metastatic MSI-H or dMMR CRC
FDA Approves New Fixed-Dose Combination for HER2+ Breast Cancer
CMS Releases Preliminary Data on Impact of COVID-19 on Medicare Population
CMS Announces New Office of Burden Reduction and Health Informatics
FDA Approves Selinexor for R/R Diffuse Large B-Cell Lymphoma
FDA Approves Tazemetostat for R/R Follicular Lymphoma
